Immunotherapy has transformed cancer care by training the body’s own immune system to recognize and destroy cancer cells. One major advancement—immune checkpoint inhibitors targeting proteins like PD-1—has delivered remarkable success in cancers such as melanoma and kidney cancer. These treatments essentially “release the brakes” on immune responses, boosting the body’s ability to fight tumors. However, they do not work for all patients or all types of cancer. This limitation has spurred global efforts to uncover new therapeutic targets.
A Breakthrough from Montréal
Researchers at the Montreal Clinical Research Institute (IRCM), led by Université de Montréal medical professor Dr. André Veillette, have made a promising discovery in this field. In a study, doctoral student Jiaxin Li and colleagues identified a novel molecule of interest—CD200R1—that may offer a new path forward for cancers that resist current treatments.
CD200R1: A New Immune Checkpoint on Macrophages
CD200R1 is a protein located on the surface of immune cells known as macrophages. These cells are critical in recognizing and eliminating abnormal or cancerous cells. The research team found that by blocking CD200R1 with specially designed antibodies, they could activate macrophages. In preclinical mouse models, this approach successfully eliminated blood cancers such as leukemia and lymphoma.
Toward New Therapies for Hard-to-Treat Cancers
As reported by medicalxpress, these findings suggest a promising new strategy to treat cancers that fail to respond to existing immunotherapies. The next phase for Veillette’s team involves collaborating with other research groups to validate this approach in human patients. If successful, this could lead to new, effective treatment options for patients with otherwise untreatable cancers.